Osteoclasts are responsible for bone resorption, and thereby play an essential role in maintain ing bone volume and homeostasis (Karsenty and Wagner, 2002) . Dysregulation of osteoclast differentiation or function disrupts mainte nance of bone homeostasis, which in turn leads to pathogenic conditions such as osteoporosis, rheumatoid arthritis, lytic bone metastases, or Paget's bone disease (Rodan and Martin, 2000) . Thus, osteoclasts could potentially be targeted therapeutically to treat skeletal disor ders. Osteoclasts originate from BM-derived monocyte/macrophage precursor cells of hema topoietic origin and are differentiated by sig naling through the receptor activator of NFB ligand (RANKL; Kong et al., 1999) . RANKL induces osteoclast differentiation by activating the nuclear factor of activated T cells 1 (NFATc1), Shinohara et al., 2008) . To identify genes potentially sup pressed after RANKL stimulation of osteoclast precursor cells (BM macrophages [BMMs] ), we undertook comparative microarray screens of BMMs treated with or without RANKL and found that expression of the transcriptional repressor Bcl6 was downregulated by RANKL ( Fig. 1 A) . Bcl6 down regulation by RANKL was confirmed by realtime RTPCR, immunofluorescence, and immunoblot analysis ( Fig. S1 and Fig. 1 B) . Immunofluorescence analysis showed that Bcl6 was detected in the nuclei of MCSF-dependent macrophages, but not in nuclei of multinuclear osteoclasts induced by RANKL (Fig. 1 B) . Interestingly, chromatin immunoprecip itation (ChIP) assays showed that, in the absence of RANKL, Bcl6 was recruited to the NFATc1 P1 promoter, a region critical for regulating NFATc1 expression in osteoclasts, and was dismissed from the promoter after RANKL treatment. In contrast, NFATc1, an essential positive regulator of osteo clastogenesis, was absent from the NFATc1 P1 promoter in the absence of RANKL, but recruited after RANKL stimula tion ( Fig. 1 C) . These results suggest a potential role of Bcl6 in inhibiting osteoclastogenesis. Bcl6 overexpression also potently inhibited osteoclast differentiation in vitro ( Fig. 1 D) , suggesting that Bcl6 negatively regulates osteoclast differenti ation and that its downregulation after RANKL stimulation is critical to induce osteoclastogenesis.
Bcl6 deficiency facilitates osteoclast formation
To characterize the physiological roles of Bcl6 in osteoclasto genesis, we analyzed Bcl6deficient (Bcl6 / ) mice. Bcl6 / mice exhibited lower bone mass as detected by microradio graphical and dualenergy xray absorptiometry analysis compared with heterozygous littermates (Bcl6 +/ ; Fig. 2 , A and B). Consistently, histomorphometric analysis of Bcl6 / mice demonstrated increased osteoclastogenesis and large osteoclast formation in Bcl6 / mice. Bcl6 / mice also showed elevated levels of serum Cterminal telopeptides of type I collagen (CTx) and decreased bone parameters (Fig. 2, C and D, and Fig. S2) . In vitro, osteoclast progenitor cells isolated from Bcl6deficient mice and treated with RANKL differen tiated more rapidly into multinuclear tartrateresistant acid phosphatase (TRAP)-positive cells than did those from con trol mice (Fig. 2 E and not depicted). Lower concentrations of RANKL not sufficient to differentiate control cells induced osteoclast differentiation of Bcl6deficient cells (Fig. 2 E) . Furthermore, increased bone resorbing activity was evident in Bcl6deficient osteoclasts (Fig. 2 F) , suggesting loss of a negative regulator of osteoclast function and differentiation. Deletion of Bcl6 in osteoclast precursor cells did not alter cell proliferation or induce apoptosis (Fig. S3) . Thus, Bcl6 func tions to regulate osteoclast differentiation and bone homeo stasis, and its downregulation by RANKL is required for osteoclast formation.
Blimp1 regulates Bcl6 expression and osteoclastogenesis
Next, we searched for a factor that might suppress Bcl6 during osteoclastogenesis and found that the transcriptional a transcription factor required for osteoclastogenesis (Takayanagi et al., 2002; Koga et al., 2004; Sato et al., 2006; Shinohara et al., 2008) . Activated NFATc1 induces expression of "osteoclastic" molecules essential for osteoclast differentiation and func tion, such as DCspecific transmembrane protein (DCSTAMP) to facilitate cell-cell fusion, cathepsin K (Ctsk) to promote bone matrix proteolysis, and NFATc1 to drive differentiation (Yagi et al., 2005; Li et al., 2006) . Thus, signaling pathways mediated by positive regulators of NFATc1 in osteoclasto genesis have been intensively studied, whereas factors nega tively modulating osteoclastogenesis are largely unknown.
B lymphocyte-induced maturation protein 1 (Blimp1) has been investigated in numerous cell types (John and GarrettSinha, 2009) and is reportedly essential for specifi cation and maintenance of primordial germ cells (PGCs) through silencing of somatic programs (Ohinata et al., 2005) . B cell lymphoma 6 (Bcl6) was originally identified as a pro tooncogene because its chromosomal translocation and con stitutive expression promotes lymphomagenesis (Ohno, 2006) . Bcl6 / mice show impaired germinal center formation (Fukuda et al., 1997) . The roles of Blimp1 and Bcl6 have also been investigated in B cell and plasma cell development (Turner et al., 1994; Fukuda et al., 1997) , as well as in T cells (Dent et al., 1998; Kusam et al., 2003; Ichii et al., 2004; Kallies et al., 2006; Martins et al., 2006; Cimmino et al., 2008) . However, the roles of Blimp1 and Bcl6, both of which are transcriptional repressors, have not previously been char acterized in osteoclastogenesis or skeletal disorders, although mutations in Bcl6associated molecules are reportedly seen in skeletal pathologies such as malformation of fingers and clav icles (Ng et al., 2004) . Recently, it was reported that inhibit ing NFATc1 using the NFATc1 inhibitor FK506 actually resulted in reduced bone mass caused by inhibition of bone formation that was more potent than inhibition of osteoclas togenesis (Koga et al., 2005) . Therefore, additional regulators of osteoclast differentiation have been sought as factors that could potentially increase bone mass.
In this study, we identify two transcriptional repressors controlling osteoclastogenesis, Bcl6 and Blimp1. We show that Bcl6 negatively regulates expression of osteoclastic genes, i.e., NFATc1, DC-STAMP, and Ctsk, which are all NFATc1 targets. We found that Bcl6 is recruited to promoters of these genes, and that Bcl6 inhibits osteoclastogenesis. We also report that Blimp1 binds to the Bcl6 promoter, likely suppressing its expression. Bcl6deficient mice exhibited decreased bone mass with increased osteoclastogenesis, whereas osteoclastspecific Blimp1 conditional KO (cKO) mice showed impaired osteo clast differentiation and increased bone mass, likely resulting from Bcl6 dysregulation. Overall, our data demonstrate that an axis of transcriptional repressors is crucial to regulate osteoclastogenesis and bone homeostasis. RANKL, Blimp1 was absent from the Bcl6 promoter, but was recruited there by RANKL treatment (Fig. S5 B) . Thus, we conclude that Bcl6 is a direct target of Blimp1 in osteoclasts.
To investigate physiological roles of Blimp1 in osteoclast differentiation, we established osteoclastspecific Blimp1 cKO mice (Ctsk Cre/+ Blimp1 flox/-), as Blimp1null mice are embry onic lethal (Vincent et al., 2005) . Blimp1 heterozygotes (Blimp1 +/ ) were crossed with CtskCre mice (Ctsk Cre/+ ) in which Cre is knocked into the Ctsk locus (Nakamura et al., 2007) . Next, Ctsk Cre/+ Blimp1 +/ mice were crossed with a transgenic strain harboring loxPflanked (floxed) Blimp1 al leles (Blimp1 flox/flox ; Ohinata et al., 2005) to yield Blimp1 cKO mice. Ctsk Cre/+ Blimp1 flox/+ mice served as controls. Blimp1 cKO mice showed increased trabecular bone mass and an expanded growth plate compared with control mice, as seen by histomorphometric and microradiographical anal ysis (Fig. 3, B-D) . TRAP staining of bone sections and anal ysis of serum CTx levels demonstrated severe inhibition of TRAPpositive osteoclast formation and bone resorbing ac tivity, respectively (Fig. 3, E and F) . Bonemorphometric analysis revealed reduced osteoblastic parameters in Blimp1 cKO mice (Fig. 3 C) . Differentiation of osteoblasts isolated from osteoclastspecific Blimp1 cKO mice did not differ repressor Blimp1, also called Prdm1, was specifically up regulated during osteoclast formation (Fig. S4 A) . Blimp1 expression in osteoclasts was also demonstrated by using Blimp1EGFP BAC transgenic mice, in which the EGFP se quence is knocked into the Blimp1 locus, and by the observa tion that TRAPpositive cells showed Blimp1 expression (Fig. S4 B) . RTPCR analysis confirmed Blimp1 induction in BMMs in the presence of RANKL in parallel with induc tion of Ctsk, a marker of osteoclast differentiation (Fig. 3 A) . To determine whether Bcl6 is a Blimp1 target, an electro phoretic mobility shift assay (EMSA) was undertaken using a Bcl6 probe corresponding to a Bcl6 regulatory region (Cimmino et al., 2008) . Blimp1 formed a complex with the probe, but not with a Bcl6mut probe in which two nucleotides are changed to disrupt the Blimp1 binding sequence (Fig. S5 A) . The PRDI probe, which corresponds to a region of the interferon  promoter known to bind Blimp1 protein (Keller and Maniatis, 1991) weakly but competitively, inhibited complex formation of the Bcl6 probe with Blimp1 ( Fig. S5 A) . In ad dition, unlabeled Bcl6 probe competed with labeled Bcl6 probe-Blimp1 to block complex formation, whereas unla beled Bcl6mut probe did not (Fig. S5 A) , confirming speci ficity and suggesting that Bcl6 is a direct Blimp1 target. Furthermore, ChIP analysis showed that, in the absence of and Bcl6 / (closed circles) mice. Data are mean BMD (mg/cm 2 ) ± SD (*, P < 0.05; **, P < 0.01; ***, P < 0.001; n = 3). (C) TRAP staining of tibial sections of Bcl6 +/ (top) and Bcl6 / (bottom) mice, and osteoclast surface as a percentage of bone surface (OcS/BS). Data are means ± SD (**, P < 0.001; n = 5). (D) Serum levels of C-terminal teropeptides of type I collagen (CTx) were analyzed in Bcl6 +/ (white bar) and Bcl6 / (shaded bar) mice. Data are means ± SD (**, P < 0.001; n = 3). (E) Osteoclast precursor cells from control (Bcl6 +/ ) or Bcl6 / mice were cultured in the presence or absence of RANKL for 5 d and subjected to May-Grünwald Giemsa and TRAP staining, and the number of multinuclear TRAP-positive cells containing more than three nuclei was determined. Data are means ± SD of cells containing more than three nuclei (**, P < 0.001; n = 3). (F) Bone resorbing activity in Bcl6 +/ (top) and Bcl6 / (bottom) osteoclasts was analyzed by a pit formation assay. Representatives of at least three (E) and two (F) independent experiments are shown. Bars: (A) 1 mm; (C, E, and F) 100 µm.
was significantly upregulated in the presence of RANKL in control cells; however, Blimp1 induction was significantly inhibited in Blimp1 cKO cells (Fig. 4 C) . In contrast, Bcl6 expression was significantly downregulated in control cells in the presence of RANKL; however, Bcl6 expression in Blimp1 cKO cells was significantly upregulated in Blimp1 cKO cells, even in the presence of RANKL (Fig. 4, C and D) , Mac1, or Gr1positive cells were normal in the Blimp1 osteo clastspecific KO, suggesting that Blimp1 is required to regu late osteoclast differentiation and bone homeostasis (Fig. S8) .
Severe inhibition of osteoclastogenesis was also observed in in vitro culture. Multinuclear TRAPpositive osteoclast formation induced by RANKL was significantly inhibited in Blimp1 cKO cells (Fig. 4, A and B) . Blimp1 expression NFATc1 (Matsumoto et al., 2004; Asagiri et al., 2005; Yagi et al., 2007) , was markedly inhibited in Blimp1 cKO osteo clasts (Fig. 5 A) . It was shown by ChIP analysis that NFATc1 was not evident on osteoclastic gene promoters without RANKL, but was recruited there after RANKL treatment of control cells (Fig. 5 B) . In contrast, in the absence of RANKL, Bcl6 was present on osteoclastic gene promoters, but was lost from those promoters after RANKL treatment of control suggesting that Blimp1 is critical to suppress Bcl6 expression in osteoclasts during differentiation by RANKL and is essen tial for regulating osteoclastogenesis. DKO mice showed accelerated osteoclastogenesis compared with those from Blimp1 cKO mice (Fig. 6 , B and C), sug gesting that Blimp1 regulates osteoclastogenesis in part through controlling Bcl6. These results reveal that the Blimp1-Bcl6-osteoclastic molecule axis is critical for control ling osteoclast differentiation and bone homeostasis (Fig. 7) .
DISCUSSION
Here, we show that two transcriptional repressors, Bcl6 and Blimp1, are essential to control physiological osteoclast de velopment and maintenance of bone homeostasis. Bcl6, a member of the POZ/BTBzinc finger protein family, sup presses expression of "osteoclastic" genes, all of which are targets of NFATc1 (Matsumoto et al., 2004; Asagiri et al., 2005; Yagi et al., 2007) , thereby antagonizing NFATc1 func tion. Indeed, NFATc1 deficiency in osteoclasts results in impaired differentiation , whereas Bcl6 deficient mice exhibit accelerated osteoclast formation and decreased bone mass. Blimp1, encoded by Prdm1, acts as a suppressor of Bcl6, likely by direct binding to the Bcl6 pro moter. In contrast to Bcl6deficient mice, osteoclastspecific Blimp1 cKO mice display impaired osteoclast differentiation and increased bone mass. Expression of Bcl6 and Blimp1 is re ciprocal in normal osteoclast formation, and unusual elevation cells (Fig. 5 B) . These data strongly indicate that NFATc1 and Bcl6 are reciprocally recruited to osteoclastic gene pro moters. Significantly, reciprocal recruitment of NFATc1 and Bcl6 was severely impaired in Blimp1 cKO cells (Fig. 5 B) , suggesting that Blimp1 upregulation is critical for loss of Bcl6 from osteoclastic promoters after RANKL stimulation. Bcl6 was not present on the NFATc2 promoter, which is not activated by RANKL stimulation , in the presence or absence of RANKL (Fig. 5 B) , suggesting that Bcl6 is selectively recruited to promoters of osteoclastic genes and inhibits osteoclast differentiation. Whereas Bcl6 was downregulated by RANKL treatment in control cells, Bcl6 expression was maintained in Blimp1 cKO cells, even in the presence of RANKL (Fig. 4 C and Fig. S9 ). These data indi cate that impaired Bcl6 downregulation caused by loss of Blimp1 results in continuous inhibition of osteoclastic gene expression, which in turn promotes severe inhibition of osteoclastogenesis and increased bone mass.
Finally, to confirm the role of Blimp1 in regulating osteo clastogenesis through Bcl6, osteoclastspecific Blimp1/Bcl6 double KO mice (double KO [DKO] ; Ctsk Cre/+ Blimp1 flox/-Bcl6 / mice) were established (Fig. 6 ). DKO mice exhibited decreased bone mass in vivo compared with Blimp1 cKO mice (Fig. 6 A) . Similarly, progenitor cells isolated from ( Baron et al., 2002; Ohno, 2006) . Blimp1 also functions in specification of the germ cell lineage and acts as a tumor sup pressor (Ohinata et al., 2005; John and GarrettSinha, 2009 ). Here, we show that Bcl6 and Blimp1, which are both impli cated in B cell and T cell development (Turner et al., 1994; Fukuda et al., 1997; Dent et al., 1998; Kusam et al., 2003; Ichii et al., 2004; Kallies et al., 2006; Martins et al., 2006; Cimmino et al., 2008) , have a novel function in regulating osteoclastogenesis and maintenance of bone homeostasis. It has been reported that Blimp1 represses Bcl6 (Cimmino et al., 2008) or that Blimp1 and Bcl6 regulate each other (Shapiro Shelef and Calame, 2005) . Blimp1 expression was reportedly inhibited by Bcl6 (Martins et al., 2006) ; however, we did not detect dysregulation of Blimp1 expression in Bcl6deficient osteoclasts (unpublished data). Osteoclastspecific Blimp1/ Bcl6 DKO mice exhibited increased osteoclastogenesis with decreased bone mass compared with Blimp1 cKO mice, in dicating that Blimp1 regulates Bcl6 in osteoclasts. However, although Bcl6deficient cells showed accelerated osteoclasto genesis compared with control cells, DKO cells showed decreased osteoclast differentiation compared with control cells, suggesting that Blimp1 regulates osteoclastogenesis through Bcl6 along with other target molecules. Blimp1 has multiple targets in lymphocytes and PGCs (Shaffer et al., 2002; Kurimoto et al., 2008) , and thus it is possible that Blimp1 has multiple targets in osteoclasts as well. In osteoclasts, several negative regulators for osteoclastogenesis, such as Id, Mafb, and Irf8, have been identified (Lee et al., 2006; Kim et al., 2007; Zhao et al., 2009 ). Blimp1 may also target these molecules in osteoclasts to stimulate osteoclast differentiation. Further in vestigations are needed to clarify the molecular mechanisms of the regulation of osteoclastogenesis by Blimp1.
We used Ctsk Cre/+ mice to establish osteoclastspecific Blimp1 cKO mice because Ctsk Cre/+ mice have been used to generate osteoclastspecific KOs of factors such as the estro gen receptor and BclXL (Nakamura et al., 2007; Iwasawa et al., 2009) . Osteoclastogenesis, including Ctsk expression, has been evaluated in osteoclastspecific genetargeted cells (Nakamura et al., 2007) . Blimp1 expression is induced earlier than Ctsk (Fig. 3 A) , and osteoclastogenesis is inhibited in Blimp1 cKO cells, suggesting that continuous Blimp1 expression is re quired for full osteoclast differentiation under control of RANKL. Blimp1 is also known to be induced by BMP4 and LIF in PGCs, where it functions as a transcriptional repressor (Ohinata et al., 2009 ). In osteoclasts, Blimp1 is induced by RANKL and acts to repress Bcl6. Thus, signaling regulating Blimp1 expression differs between PGCs and osteoclasts.
Bone homeostasis requires a delicate balance between os teoclastic and osteoblastic activities. A decline in bone vol ume is closely related to upregulation of osteoclast activity, and thus osteoclasts could be targeted therapeutically to treat skeletal disorders such as osteoporosis and destructive bone metastasis. FK506, a specific inhibitor of calcineurinNFATs, inhibits osteoclastogenesis, but does not increase bone mass, as FK506 also inhibits bone formation (Koga et al., 2005) . Thus, additional factors that could negatively regulate osteoclast of Bcl6 expression caused by Blimp1 deficiency leads to osteoclastogenesis failure, as indicated by increased bone mass seen in a Blimp1 cKO model. Signals positively regulating NFATc1 in osteoclasts, such as TRAF6, cFos, ITAM PLCCa 2+ signals, Btk, and Tec (Takayanagi et al., 2002; Koga et al., 2004; Shinohara et al., 2008) , have been charac terized, and NFATc1 reportedly positively autoregulates in osteoclasts . However, factors modulat ing this activity have not been described. Our study charac terizes such an axis of factors that serve as a molecular switch to control osteoclastogenesis and bone homeostasis after RANKL stimulation.
To date, the skeletal and immune systems have been shown to share common molecules to achieve homeostasis (Nakashima and Takayanagi, 2008) . RANKL and RANK were originally identified in T cells and DCs (Anderson et al., 1997) , respectively, and both are essential for osteoclastogen esis (Kong et al., 1999; Dougall et al., 1999) . NFATc1 was identified in T cells and plays an essential role in osteoclast formation (Northrop et al., 1994; Asagiri et al., 2005) . DC STAMP plays a role in DC function and is required for cellcell fusion of osteoclasts and macrophage giant cells (Yagi et al., 2005 (Yagi et al., , 2007 Sawatani et al., 2008) . Besides roles in immune system, Bcl6 has antiapoptotic and protooncogenic function serially diluted products using the same PCR reactions. -actin expression served as an internal control. Primer sequences were as follows: -actin for ward: 5TGAGAGGGAAATCGTGCGTGAC3; -actin reverse: 5AA GAAGGAAGGCTGGAAAAGAG3; Bcl6 forward: 5AGACGCACAGT GACAAACCATACAA3; Bcl6 reverse: 5GCTCCACAAATGTTACA GCGATAGG3; Blimp1 forward: 5TTCTTGTGTGGTATTGTCGGGA CTT3; Blimp1 reverse: 5TTGGGGACACTCTTTGGGTAGAGTT3; Ctsk forward: 5ACGGAGGCATTGACTCTGAAGATG3; Ctsk reverse: 5GGAAGCACCAACGAGAGGAGAAAT3; DC-STAMP for ward: 5TCCTCCATGAACAAACAGTTCCAA3; DC-STAMP re verse: 5AGACGTGGTTTAGGAATGCAGCTC3; NFATc1 forward: 5CAAGTCTCACCACAGGGCTCACTA3; NFATc1 reverse: 5GCG TGAGAGGTTCATTCTCCAAGT3; type I collagen forward: 5CCTGG TAAAGATGGTGCC3; type I collagen reverse: 5CACCAGGTTCAC CTTTCGCACC3; osteocalcin forward: 5TAGCAGACACCATGAGGA CCCT3; osteocalcin reverse: 5TGGACATGAAGGCTTTGTCAGA3.
Immunofluoresence. Cells were fixed with 4% paraformaldehyde (Wako Pure Chemical Industries) in PBS solution for 15 min at room temperature. After washing to remove fixation solution, cells were permeabilized in PBS containing 0.1% Triton X100 for 10 min at room temperature and then washed. Nonspecific antibody binding was blocked by treatment with 5% BSA (SigmaAldrich Co.) in PBS. Cells were then stained with antiBcl6 antibody (1:50 dilution, N3; Santa Cruz Biotechnology, Inc.) at 4°C over night, washed with PBS and stained with Alexa Fluor 546-conjugated anti rabbit IgG antibody (1:200 dilution) for 1 h at room temperature. Cells were washed to remove secondary antibody and incubated with DAPI solution (Dojindo Co.; 1:5,000) for nuclear staining, followed by microscopic obser vation (model BZ9000; Keyence Co).
Immunoblotting analysis. Wholecell lysates were prepared from BM cultures using RIPA buffer (1% Triton X100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM TrisHCl, pH 7.5, 5 mM EDTA, and a protease inhibitor cocktail; SigmaAldrich). Equivalent amounts of protein were separated by SDSPAGE and transferred to a PVDF membrane (Millipore). Proteins were detected using the following antibodies: antiNFATc1 (7A6), antiBlimp1 (6D3), antiBcl6 (N3) (Santa Cruz Biotechnology, Inc.), and antiactin (A2066; SigmaAldrich).
EMSA. Nuclear extracts were prepared from COS7 cells transfected with pCAGHABlimp1 or pCAG. Each extract was incubated for 30 min on ice with a [ 32 P]labeled probe in binding buffer (10 mM TrisHCl, pH 7.9, 50 mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 10% glycerol) containing 2 µg of poly(dIdC), KCl, and BSA. Complexes were separated on 5% polyacryl amide gels in TGE buffer (25 mM TrisHCl, 190 mM glycine, and 1 mM EDTA). The Bcl6 probe corresponding to a putative Blimp1 binding site in the Bcl6 gene was 5AGGTTTCATAGGAAGTGAAAACCCTGCTAT3. A mutated probe (underlined residues) served as a negative control (Bcl6mut probe; 5AGGTTTCATAGGAAGTTAGAACCCTGCTAT3). After electrophoresis, gels were dried and exposed to the imaging plate, and signals were analyzed using ImageGauge software on the BAS2000 image ana lyzer (Fuji Film Co.).
ChIP. ChIP was performed on osteoclasts. MCSF-induced BMMs were cultured on 100mm type I collagencoated culture dishes (Asahi Glass Co.) with MCSF and recombinant RANKL for the indicated time periods, and then subjected to ChIP analysis using the ChIPIT Enzymatic kit (ActivMotif Inc.), according to the manufacturer's instructions. Immuno precipitation was performed using antiNFATc1 (7A6), antiBcl6 (N3), and antiBlimp1 (C14A4; Cell Signaling Technology). DNA was pu rified by QIAquick PCR purification kit (QIAGEN) and analyzed using primers corresponding to the following promoters: NFATc1P1 promoter, 5CCGGGACGCCCATGCAATCTGTTAGTAATT3 (sense) and 5GCGGGTGCCCTGAGAAAGCTACTCTCCCTT3 (antisense); the DC-STAMP promoter, 5GGGGGTCCTCATTTCTACAACTCAT3 differentiation, such as those identified here, have been sought. Thus, our study provides new insight into regulation of osteoclastogenesis and bone homeostasis and forms the basis for developing novel therapeutic approaches to treat skeletal disorders.
MATERIALS AND METHODS
Mice. Bcl6 / mice on a mixed C57BL/6 X 129/Sv background were gen erated by crossing Bcl6 heterozygotes (Bcl6 +/ ; Fukuda et al., 1997) . Osteo clastspecific Blimp1 cKO mice on a C57BL/6 background were generated from three lines: mice carrying loxPflanked Blimp1 alleles (Blimp1 flox/flox ; Ohinata et al., 2005) , mice harboring Cre in the Ctsk (Ctsk Cre/ ) locus (Nakamura et al., 2007) , and Blimp1 heterozygotes (Blimp1 +/ ; provided by A. Tarakhovsky, The Rockefeller University, New York, NY). Animals were maintained under specific pathogen-free conditions in animal facilities certified by the Keio University School of Medicine animal care committee. Animal protocols were approved by the Keio University School of Medicine animal care committee.
In vitro osteoclast formation. BM cells isolated from long bones (femurs, tibias, and humerus) were cultured 72 h in MEM (SigmaAldrich) contain ing 10% heatinactivated FBS (JRH Biosciences) and GlutaMax supple mented with MCSF (50 ng/ml; Kyowa Hakko Kirin Co.). Adherent cells were then collected for analysis. 10 5 cells were cultured with MCSF and recombinant soluble RANKL (25 ng/ml; PeproTech Ltd.) for indicated time periods. Mouse spleen cells were cultured overnight in MEM con taining 10% heatinactivated FBS and GlutaMax supplemented with MCSF. After this incubation, nonadherent cells were collected and 10 5 cells were cultured with MCSF and recombinant soluble RANKL (5 or 25 ng/ml) for the indicated time periods. Osteoclastogenesis was evaluated by TRAP and MayGrünwald Giemsa staining (Miyamoto et al., 2000; Yagi et al., 2005) . RAW264.7 cells were maintained in MEM containing 10% heatinactivated FBS and GlutaMax and stimulated by recombinant soluble RANKL to induce osteoclast formation.
Pit formation assay. Bone resorbing activity of osteoclasts was analyzed as previously described (Iwamoto et al., 2004) . In brief, osteoclast precursors isolated from indicated mice were seeded on dentin slices and cultured in the presence of MCSF plus RANKL for 6 d. Dentin slices were then stained by toluidine blue and observed under a microscope (model BZ9000; Keyence Co.).
Analysis of skeletal morphology. Bcl6 / , DKO, and control littermates were necropsied 16 d after birth. Hindlimbs were removed, fixed with 70% ethanol, and subjected to dualenergy xray absorptiometry analysis to mea sure bone mineral density and for bonehistomorphometric analysis. Female 8wkold Blimp1 cKO mice and control littermates were administered intraperitoneal injections of 16 mg/kg calcein (Dojindo Co.) at 6 and 1 d before sacrifice to evaluate bone formation rate. Hindlimbs were removed and analyzed as described above.
ELISA. Serum levels of osteocalcin and Cterminal telopeptides of type I col lagen (CTx) were measured by the Mouse Osteocalcin EIA kit (Biomedical Technologies Inc.) and RatLaps EIA (Immunodiagnostics Systems Ltd.), re spectively. Assays were undertaken following the manufacturers' instructions.
Real-time PCR analysis. Total RNAs were isolated from BM cultures by TRIzol reagent (Invitrogen). After denaturation of total RNAs at 70°C for 5 min, cDNAs were synthesized from total RNAs using oligo(dT) primer and reverse transcription (Wako Pure Chemicals Industries). Realtime PCR was performed using SYBR Premix ExTaq II (Takara Bio Inc.) with the DICE Thermal cycler (Takara Bio Inc.), according to the manufacturer's instructions. Samples were matched to a standard curve generated by amplifying Microarray analysis. BM cells were isolated from 8wkold mouse and cultured in the presence of MCSF for 3 d. MCSF-dependent adherent cells were harvested and cultured with MCSF alone for macrophages and MCSF plus RANKL for osteoclasts, respectively. After 6 days of cultiva tion, total RNA was isolated and microarray analysis was undertaken using GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Data were analyzed using GeneChip Operating Software and deposited in Minimum Informa tion about a Microarray Experiment compliant in Gene Expression Omni bus (GEO accession no. GSE20850).
Online supplemental material. Fig. S1 shows that Bcl6 is transcription ally repressed by RANKL. Fig. S2 shows bone parameters of Bcl6 +/ and Bcl6 / mice. Fig. S3 shows proliferation and apoptosis of osteoclast precur sors from Bcl6 +/ and Bcl6 / mice. Fig. S4 shows Blimp1 expression in osteoclasts. Fig. S5 shows that Blimp1 binds to the Bcl6 promoter. Fig. S6 shows normal osteoblastic differentiation in Blimp1 cKO cells. Fig. S7 shows proliferation and apoptosis of osteoclast precursors from Blimp1 cKO and control mice. Fig. S8 shows immune cell populations in spleens of Blimp1 cKO and control mice. Fig. S9 shows dysregulation of Bcl6 in Blimp1 cKO BMM. Online supplemental material is available at http://www.jem .org/cgi/content/full/jem.20091957/DC1.
